BNP Paribas Maintains Neutral on Medline, Lowers Price Target to $40
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
BNP Paribas analyst Navann Ty maintains Medline (NASDAQ:MDLN) with a Neutral and lowers the price target from $49 to $40.
BNP Paribas analyst Navann Ty maintains Medline (NASDAQ:MDLN) with a Neutral and lowers the price target from $49 to $40.